# QUIDELORTHO CORP (QDEL) · Edgar & Edgarette company card

> Quidelortho (QDEL) saw revenue fall 1.9% in FY2025 to $2.7 billion, operating margin -33.7% against a -4.3% median for in vitro & in vivo diagnostic substances, equity 33.3% of assets. Every figure is from the company’s own annual report filed with the SEC.

SEC CIK 1906324 · fiscal year ended 2025-12-28 · 5 audited years read · [page](https://www.pops4.com/boards/company/QDEL) · [JSON](https://www.pops4.com/boards/company/QDEL.json)

## Figures, as filed in the 10-K

| Measure | Value |
|---|---|
| Revenue | $2.7B |
| Revenue growth, 1 year | -1.9% |
| Revenue growth per year | 12.6% |
| Operating margin | -33.7% (prior year -70.5%) |
| Net margin | -41.5% |
| Operating cash flow | $105M |
| Capital spending | $188M |
| Free cash flow | −$83M |
| Cash | $170M |
| Long-term debt | $2.7B |
| Total assets | $5.8B |
| Total equity | $1.9B |
| Equity ÷ assets | 33.3% |
| Return on equity | -58.9% |
| Dividend per share | — |
| Dividend years rising | — |

## Readings, computed from those figures

- Altman Z: -0.56 (distress zone)
- Piotroski F: 5 of 9 (middling)
- Health Harbor boat: Rotting at the dock · four or more warning signs · slow and jumpy: growing slower than its size class, with revenue that swings more; operating loss: a margin of -33.7% in FY2025; free cash flow was negative: capital spending outran operating cash (-$83.0M in FY2025); revenue is hard to predict: its 80% range is ±35%
- Cash Compass: Fading · slow and jumpy, lagging its peers

## Edgarette's reading

Exposure: revenue $2.7B (FY2025), total debt $2.7B. Experience: revenue down 1.9% on the year, up 12.6% a year over 4 years; operating margin -33.7%, up from -70.5%. Soundness: equity 33.3% of assets, return on equity -58.9%. Credibility: four or more audited years, reasonable weight. Range: 80% of past cases like this landed between $1.8B and $3.7B next year (method v4.1: its own 5-year record of growth weighed at 57% against $1B–10B filers; across 2019–2025, 69.0% landed inside, 83.4% on the one year the method never saw). In a shock year the stress range is $1.4B to $4.9B. A statistical range, not company guidance. Against peers (161 filers, $50M+ revenue, its industry group): operating margin -33.7% against a -4.3% median; growth -1.9% against 12.6%.

Range logged 2026-09-24, receipt 9760767760676375, status open. A statistical range, not company guidance.

## Health Watch, last 12 months

- Item 5.02 Director or officer change: 5, latest 2026-11-03 ([filing](https://www.sec.gov/Archives/edgar/data/1906324/000190632426000040/0001906324-26-000040-index.htm))

## Recent filings

- 10-Q · filed 2026-11-04 · [filing](https://www.sec.gov/Archives/edgar/data/1906324/000190632426000042/0001906324-26-000042-index.htm)
- 8-K · filed 2026-11-03 · 2.02 Results of Operations and Financial Condition; 5.02 Departure or Election of Directors; Appointment of Officers; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/1906324/000190632426000040/0001906324-26-000040-index.htm)
- 8-K · filed 2026-09-23 · 1.01 Entry into a Material Definitive Agreement; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/1906324/000190632426000036/0001906324-26-000036-index.htm)
- 10-Q · filed 2026-08-07 · [filing](https://www.sec.gov/Archives/edgar/data/1906324/000190632426000033/0001906324-26-000033-index.htm)
- 8-K · filed 2026-08-06 · 2.02 Results of Operations and Financial Condition; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/1906324/000190632426000032/0001906324-26-000032-index.htm)
- 8-K · filed 2026-06-23 · 5.02 Departure or Election of Directors; Appointment of Officers; 7.01 Regulation FD Disclosure; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/1906324/000190632426000028/0001906324-26-000028-index.htm)

## Sources

- facts: https://data.sec.gov/api/xbrl/companyfacts/CIK0001906324.json
- filings: https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=1906324

## Cite

POPS4, Edgar & Edgarette: QUIDELORTHO CORP (QDEL) company card, from the company's own SEC filings, accessed 2026-11-08, https://www.pops4.com/boards/company/QDEL. CC BY 4.0. For a figure, add the filing URL under filings or sources.

DOI https://doi.org/10.5281/zenodo.23672509 · catalog https://www.pops4.com/boards/catalog.json · Figures as filed with the SEC. Card text CC BY 4.0, POPS4.

Reporting, not investment advice. No price targets and no trading recommendations.

Figures are as filed in audited 10-K reports and can move with restatements, acquisitions, disposals or a change in fiscal year. A range set from how past company-years turned out is not a promise about the next one, and says nothing about the share price.